Clinical Outcome of Renal Artery Stenting for Hypertension and Chronic Kidney Disease up to 12 Months in the J-RAS Study : Prospective, Single-Arm, Multicenter Clinical Study

• Fujihara Masahiko

  Kishiwada Tokushukai Hospital Cardiovascular Center

• Yokoi Yoshiaki

  Kishiwada Tokushukai Hospital Cardiovascular Center

• Abe Takaaki

  Tohoku University Graduate School of Medicine

• Soga Yoshimitsu

  Kokura Memorial Hospital

• Yamashita Takehiro

  Cardiovascular Center, Hokkaido Ohno Hospital

• Miyashita Yusuke

  Shinshu University Hospital

• Nakamura Masato

  Toho University Ohashi Medical Center

• Yokoi Hiroyoshi

  Fukuoka Sanno Hospital

• Ito Sadayoshi

  Tohoku University Graduate School of Medicine

• on behalf of the J-RAS Study Investigators

• Yamamoto K

• Ishikawa T

• Ando H

• Kasayuki N

• Taniguchi N

• Sasaki S

• Munemasa M

• Takahashi H

• Miki K

• Ikari Y

• Okutsu M

• Jujo K

• Zen K

• Hirabayashi T

• Asahi H

• Oda H

• Uesugi M

• Matsumoto Y

• Shintani Y

書誌事項

タイトル別名

• Clinical Outcome of Renal Artery Stenting for Hypertension and Chronic Kidney Disease up to 12 Months in the J-RAS Study
• Clinical outcome of renal artery stenting for hypertension and chronic kidney disease up to 12 months in the J-RAS Study—prospective, single-arm, multicenter clinical study
• – Prospective, Single-Arm, Multicenter Clinical Study –

抄録

Background:Atherosclerotic renal artery stenosis (ARAS) causes renovascular hypertension (HTN) and impairs renal function, leading to chronic kidney disease (CKD). The J-RAS study was a prospective, multicenter study to assess the clinical outcome of renal artery stenting for up to 1 year in Japanese patients with ARAS.Methods and Results:One hundred and forty-nine patients were enrolled between November 2010 and January 2013. The patients were classified into an HTN (n=121) group and a CKD (n=108) group in the primary analysis. The primary efficacy endpoints were change in blood pressure for the HTN group and change in estimated glomerular filtration rate (eGFR) for the CKD group at 1 months. The primary safety endpoint was freedom from major cardiovascular or renal events at 12 months. In the HTN group, the mean systolic blood pressure (SBP) significantly decreased from 161.6±21 mmHg at baseline to 137.0±21 mmHg (P<0.0001). In the CKD group, there was no significant difference in eGFR from 40.7±10 ml·min⁻¹·1.73 m⁻²at baseline to 40.8±13 ml·min⁻¹·1.73 m⁻²(P=0.32). The primary safety endpoint was 89.4% at 12 months.Conclusions:In the J-RAS trial, significant SBP reduction was seen in the HTN group, and stabilization of renal function in the CKD group. Renal artery stenting for ARAS is safe and effective in Japanese patients. (Circ J 2015; 79: 351–359)

収録刊行物

• Circulation Journal

  Circulation Journal 79 (2), 351-359, 2015

  一般社団法人 日本循環器学会

キーワード

• Atherosclerotic renal artery stenosis
• Chronic kidney disease
• Hypertension
• Renal artery stenting

詳細情報

• CRID: 1390282680085180672
• NII論文ID: 130004704043
• NII論文ID: 40020333950
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-14-0908
• ISSN: 13474820
• ISSN: 13469843
• NDL書誌ID: 026048955
• PubMed: 25476409
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I026048955
• Web Site: https://www.jstage.jst.go.jp/article/circj/79/2/79_CJ-14-0908/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2015295087
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可